Cette recherche s'applique uniquement aux ressources en bibliothèque.
2 277 résultats
Trier par:
Ajouter à la liste:
Étendre à toutes les références (sans texte intégral)
    • Plusieurs versions

    Introduction to the supplement, “Cancer Therapy with Antibodies and Immunoconjugates”

    Goldenberg, David M.
    Cancer, 15 February 2010, Vol.116(S4), pp.1011-1012 [Revue évaluée par les pairs]

    • Plusieurs versions

    Radiopharmaceutical therapy in the era of precision medicine

    Sgouros, George, Goldenberg, David M
    European journal of cancer (1990), September 2014, Vol.50(13), pp.2360-2363 [Revue évaluée par les pairs]

    • Article
    Sélectionner

    Anti-CD22/CD20 Bispecific Antibody with Enhanced Trogocytosis for Treatment of Lupus (Anti-CD22/CD20 Bispecific Antibody for Treatment of Lupus)

    Rossi, Edmund A, Chang, Chien-Hsing, Goldenberg, David M
    2014, Vol.9(5), p.e98315 [Revue évaluée par les pairs]
    PLoS
    Disponible
    Plus…
    Titre: Anti-CD22/CD20 Bispecific Antibody with Enhanced Trogocytosis for Treatment of Lupus (Anti-CD22/CD20 Bispecific Antibody for Treatment of Lupus)
    Auteur: Rossi, Edmund A; Chang, Chien-Hsing; Goldenberg, David M
    Contributeur: Bachmann, Michael P. (Editor)
    Sujet: Research Article ; Biology And Life Sciences ; Engineering And Technology ; Medicine And Health Sciences ; Research And Analysis Methods
    Description: The humanized anti-CD22 antibody, epratuzumab, has demonstrated therapeutic activity in clinical trials of lymphoma, leukemia and autoimmune diseases, treating currently over 1500 cases of non-Hodgkin lymphoma, acute lymphoblastic leukemias, Waldenström’s macroglobulinemia, Sjögren’s syndrome, and systemic lupus erythematosus. Because epratuzumab reduces on average only 35% of circulating B cells in patients, and has minimal antibody-dependent cellular cytotoxicity and negligible complement-dependent cytotoxicity when evaluated in vitro , its therapeutic activity may not result completely from B-cell depletion. We reported recently that epratuzumab mediates Fc/FcR-dependent membrane transfer from B cells to effector cells via trogocytosis, resulting in a substantial reduction of multiple BCR modulators, including CD22, CD19, CD21, and CD79b, as well as key cell adhesion molecules, including CD44, CD62L, and β7 integrin, on the surface of B cells in peripheral blood mononuclear cells obtained from normal donors or SLE patients. Rituximab has clinical activity in lupus, but failed to achieve primary endpoints in a Phase III trial. This is the first study of trogocytosis mediated by bispecific antibodies targeting neighboring cell-surface proteins, CD22, CD20, and CD19, as demonstrated by flow cytometry and immunofluorescence microscopy. We show that, compared to epratuzumab, a bispecific hexavalent antibody comprising epratuzumab and veltuzumab (humanized anti-CD20 mAb) exhibits enhanced trogocytosis resulting in major reductions in B-cell surface levels of CD19, CD20, CD21, CD22, CD79b, CD44, CD62L and β7-integrin, and with considerably less immunocompromising B-cell depletion that would result with anti-CD20 mAbs such as veltuzumab or rituximab, given either alone or in combination with epratuzumab. A CD22/CD19 bispecific hexavalent antibody, which exhibited enhanced trogocytosis of some antigens and minimal B-cell depletion, may also be therapeutically useful. The bispecific antibody is a candidate for improved treatment of lupus and other autoimmune diseases, offering advantages over administration of the two parental antibodies in combination.
    Fait partie de: 2014, Vol.9(5), p.e98315
    Identifiant: 1932-6203 (E-ISSN); 10.1371/journal.pone.0098315 (DOI)

    • Plusieurs versions

    Anti-CD22/CD20 Bispecific Antibody with Enhanced Trogocytosis for Treatment of Lupus

    Rossi, Edmund A, Chang, Chien-Hsing, Goldenberg, David M
    PLoS ONE, 2014, Vol.9(5) [Revue évaluée par les pairs]

    • Plusieurs versions

    Improving the treatment of non‐Hodgkin lymphoma with antibody‐targeted radionuclides

    Sharkey, Robert M., Karacay, Habibe, Goldenberg, David M.
    Cancer, 15 February 2010, Vol.116(S4), pp.1134-1145 [Revue évaluée par les pairs]

    • Plusieurs versions

    PAM4 enzyme immunoassay alone and in combination with CA 19‐9 for the detection of pancreatic adenocarcinoma

    Gold, David V., Gaedcke, Jochen, Ghadimi, B. Michael, Goggins, Michael, Hruban, Ralph H., Liu, Mengling, Newsome, Guy, Goldenberg, David M.
    Cancer, 01 February 2013, Vol.119(3), pp.522-528 [Revue évaluée par les pairs]

    • Plusieurs versions

    Horizontal Transmission of Malignancy: In-Vivo Fusion of Human Lymphomas with Hamster Stroma Produces Tumors Retaining Human Genes and Lymphoid Pathology

    Goldenberg, David M, Gold, David V, Loo, Meiyu, Liu, Donglin, Chang, Chien-Hsing, Jaffe, Elaine S
    PLoS ONE, 2013, Vol.8(2) [Revue évaluée par les pairs]

    • Plusieurs versions

    Interferon-λ1 linked to a stabilized dimer of Fab potently enhances both antitumor and antiviral activities in targeted cells

    Liu, Donglin, Chang, Chien-Hsing, Rossi, Edmund A, Cardillo, Thomas M, Goldenberg, David M
    PloS one, 2013, Vol.8(5), pp.e63940 [Revue évaluée par les pairs]

    • Plusieurs versions

    In-vivo fusion of human cancer and hamster stromal cells permanently transduces and transcribes human DNA

    Goldenberg, David M, Rooney, Robert J, Loo, Meiyu, Liu, Donglin, Chang, Chien-Hsing
    PloS one, 2014, Vol.9(9), pp.e107927 [Revue évaluée par les pairs]

    • Plusieurs versions

    Evaluation of a Novel Hexavalent Humanized Anti-IGF-1R Antibody and Its Bivalent Parental IgG in Diverse Cancer Cell Lines (Novel Humanized Antibodies Targeting IGF-1R)

    Chang, Chien-Hsing, Wang, Yang, Trisal, Preeti, Li, Rongxiu, Rossi, Diane L, Nair, Anju, Gupta, Pankaj, Losman, Michele, Cardillo, Thomas M, Rossi, Edmund A, Goldenberg, David M
    2012, Vol.7(8), p.e44235 [Revue évaluée par les pairs]